Filtered By:
Condition: Hypertension
Procedure: Heart Transplant
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 156 results found since Jan 2013.
Diet Beverages Linked To Increased Stroke Risk & Heart Attacks
This study, as well as other research on the connection between diet beverages and vascular disease, is observational and cannot show cause and effect. That’s a major limitation, researchers say, as it’s impossible to determine whether the association is due to a specific artificial sweetener, a type of beverage or another hidden health issue.
“Postmenopausal women tend to have higher risk for vascular disease because they are lacking the protective effects of natural hormones,” North Carolina cardiologist Dr. Kevin Campbell said, which could contribute to increased risk for heart disease and stroke...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 14, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Heart Attack Stroke Source Type: news
Diet Drinks Linked To Increased Stroke Risk & Heart Attacks
This study, as well as other research on the connection between diet beverages and vascular disease, is observational and cannot show cause and effect. That’s a major limitation, researchers say, as it’s impossible to determine whether the association is due to a specific artificial sweetener, a type of beverage or another hidden health issue.
“Postmenopausal women tend to have higher risk for vascular disease because they are lacking the protective effects of natural hormones,” North Carolina cardiologist Dr. Kevin Campbell said, which could contribute to increased risk for heart disease and stroke...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 14, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Heart Attack Stroke Source Type: news
Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research
Conclusion
The high prevalence of comorbidities in patients with stroke indicates the need for therapies in preclinical studies that take into account these comorbidities in order to avoid failures in translation to the patient. Preclinical studies are beginning to evaluate the efficacy of MSC treatment in stroke associated with comorbidities, especially hypertension, for ischemic and hemorrhagic stroke. Regarding aging and diabetes, only ischemic stroke studies have been performed. For the moment, few studies have been performed and contradictory results are being reported. These contradictory results may be due to the u...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research
Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke
Conclusions: We developed an index to measure gut microbiota dysbiosis in stroke patients; this index was significantly correlated with patients' outcome and was causally related to outcome in a mouse model of stroke. Our model facilitates the potential clinical application of gut microbiota data in stroke and adds quantitative evidence linking the gut microbiota to stroke.
Introduction
Ischemic stroke imposes a heavy burden on society, with 24.9 million cases worldwide (1). Although intravenous thrombolysis and endovascular treatment greatly improve some patients' prognosis, the prognosis for most pa...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research
Conveniently-Grasped Field Assessment Stroke Triage (CG-FAST): A Modified Scale to Detect Large Vessel Occlusion Stroke
Conclusions: CG-FAST scale could be an effective and simple scale for accurate identification of LVOS among AIS patients.
Introduction
Large vessel occlusion stroke (LVOS) often leads to severe disability and mortality. Although endovascular therapy (EVT) has been proved to be effective for LVOS patients (1–9), especially in anterior circulation, its benefit is highly time-dependent (10, 11). As hospitals with around-the-clock endovascular capability are scarce in many parts of the world and patients admitted directly to a CSC would have better outcomes than those receiving drip and ship treatment (12, 13), t...
Source: Frontiers in Neurology - April 16, 2019 Category: Neurology Source Type: research
Reported link between diet drinks and dementia and stroke is weak
Conclusion
The researchers used data from a large ongoing cohort study to look for links between consumption of sugary and artificially sweetened drinks and risk of stroke or dementia.
This cohort study benefits from the large overall sample size, long period of data collection, careful and valid diagnostic assessments, and adjustments for a number of confounders. However, care must be taken when interpreting these results – particularly if latching on to the maximal tripled risk figures reported in the media.
There are several points to consider:
Small numbers
The new number of strokes and dementia in this study was sma...
Source: NHS News Feed - April 21, 2017 Category: Consumer Health News Tags: Food/diet Heart/lungs Neurology Source Type: news
Endothelial Progenitor Cells: Therapeutic Perspective for Ischemic Stroke.
Abstract
Endothelial progenitor cells (EPCs), which can be cultured in vitro from mononuclear cells in peripheral blood or bone marrow, express both hematopoietic stem cell and endothelial cell markers on their surface. They are believed to participate in endothelial repair and postnatal angiogenesis due to their abilities of differentiating into endothelial cells and secreting protective cytokines and growth factors. Mounting evidence suggests that circulating EPCs are reduced and dysfunctional in various diseases including hypertension, diabetes, coronary heart disease, and ischemic stroke. Therefore, EPCs have ...
Source: CNS Neuroscience and Therapeutics - December 11, 2012 Category: Neuroscience Authors: Zhao YH, Yuan B, Chen J, Feng DH, Zhao B, Qin C, Chen YF Tags: CNS Neurosci Ther Source Type: research
Elevated Blood Pressure Before Left Ventricular Assist Device Support Implant is Associated with an Increased Risk of Stroke
Despite the recent advances in Left Ventricular Assist Device (LVAD) therapy, stroke remains a frequent and catastrophic complication. Hypertension (HTN) after LVAD implant has been associated with an increased risk of stroke, but the association between HTN before LVAD implant and stroke has never been studied. We hypothesized that LVAD patients with elevated blood pressure (BP) during outpatient visits before the LVAD implant may have an increased risk of stroke.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: F. Castagna, S. Patel, S. Vukelic, S. Madan, O. Saeed, D. Sims, D. Goldstin, U.P. Jorde Tags: (978) Source Type: research
Stroke epidemiology and outcomes in the modern era of left ventricular assist devices
AbstractThe care for the patients with end-stage heart failure has been revolutionized by the introduction of durable left ventricular assist devices, providing a substantial improvement in patient survival and quality of life and an alternative to heart transplantation. The newest devices have lower instances of mechanical dysfunction and associated pump thrombosis. Despite these improvements in complications, the use of continuous flow assist devices is still associated with high rates of thrombotic and hemorrhagic complications, most notably stroke in approximately 10% of continuous flow assist devices patients per year...
Source: Heart Failure Reviews - January 16, 2022 Category: Cardiology Source Type: research
Systolic Blood Pressure on Discharge after Left Ventricular Assist Device Insertion is Associated with Subsequent Stroke
Stroke is a significant complication in patients supported with continuous-flow left ventricular assist devices (CF-LVAD) and hypertension (HTN) is a significant risk factor for stroke, but the association between blood pressure and stroke in LVAD patients is not well characterized.
Source: The Journal of Heart and Lung Transplantation - October 22, 2014 Category: Transplant Surgery Authors: Michael E. Nassif, Anjan Tibrewala, David S. Raymer, Adam Andruska, Eric Novak, Justin M. Vader, Akinobu Itoh, Scott C. Silvestry, Gregory A. Ewald, Shane J. LaRue Source Type: research
Stroke Volume Response to Exercise is Dependent on Disease Severity in Pulmonary Arterial Hypertension
This study aimed to describe changes in stroke volume (SV) during exercise in patients with pulmonary arterial hypertension (PAH) to allow for exercise-based risk stratification.
Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: C. G öransson, N. Vejlstrup, J. Carlsen Source Type: research
Neurological Involvement in Primary Systemic Vasculitis
Conclusion
Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases.
TABLE 1
Table 1. Common CNS and PNS involvements of primary systemic vasculitis.
Author Contributions
SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
